// App-Quantinova.ai

4524 : Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).

Researchers

Presenter

  • Jacqueline Vuky

Principal Investigators

  • Arjun Vasant Balar

  • Daniel E. Castellano

  • Peter H. O'Donnell

  • Petros Grivas

  • Joaquim Bellmunt

  • Thomas Powles

  • Dean F. Bajorin

  • Noah M. Hahn

  • Ronald De Wit

  • Mary Savage

  • Lei Pang

  • Tara L. Frenkl

  • Stephen Michael Keefe

  • Elizabeth R. Plimack

Medical Centers

  • Oregon Health and Science University, Portland, OR

  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • The University of Chicago Medical Center, Chicago, IL

  • Cleveland Clinic, Cleveland, OH

  • Dana-Farber Cancer Institute, Boston, MA

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

  • Merck & Co., Inc., Kenilworth, NJ

  • Fox Chase Cancer Center, Philadelphia, PA

Locations

  • United States

  • Spain

  • United Kingdom

  • Netherlands

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • II

Study Id's

  • NCT02335424

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved